<DOC>
	<DOCNO>NCT01095588</DOCNO>
	<brief_summary>This study design look effect avanafil blood level warfarin investigate effect prothrombin time/international normalize ratio ( INR ) healthy men .</brief_summary>
	<brief_title>Study Effect Avanafil Pharmacodynamics Pharmacokinetics Warfarin Healthy Male Subjects</brief_title>
	<detailed_description>The trial single-centre , double-blind , randomize , placebo-controlled , 2-way crossover drug interaction study least 21-day washout period . Each subject participate two session randomize receive either 200 mg avanafil match placebo 9 day . On Day 3 period , subject receive single dose warfarin ( 25 mg ) . Following warfarin dose , pharmacokinetic pharmacodynamic sample take period 7 day . Subjects discharge Day 10 follow end-of-period evaluation . There washout least 21 day warfarin dos . The study medication administer 240 mL water follow overnight fast least 10 hour . Blood sample ( 3 mL ) assessment R- S-warfarin concentration plasma draw Day 3 prior warfarin administration 0.5 , 1 , 1.5 , 2 , 4 , 6 , 9 , 12 , 24 , 48 , 72 , 96 , 120 , 144 , 168 hour warfarin administration . Blood sample ( 3 mL ) assessment avanafil and/or metabolite concentration draw Day 3 prior avanafil ( placebo ) administration 0.5 , 1 , 2 hour post-dose . Blood sample ( 4.5 mL ) assessment prothrombin time ( PT ) international normalize ratio ( INR ) drawn screening , check-in , Day 3 prior warfarin administration 6 , 12 , 24 , 36 , 48 , 72 , 96 , 120 , 144 , 168 hour post-dose . Blood sample ( 4.5 mL ) collagen-induced platelet aggregation draw Day 3 prior warfarin administration 1 , 4 , 6 , 12 , 24 hour post-dose . A blood sample ( 8.5 mL ) VKORC1 CYP2C9 genotyping draw check-in Period 1 . The overall blood volume require study ( assume direct venipuncture sample ) approximately 446 mL . All subject confine Clinical Research Unit start Day -2 diet equilibration remain confine approximately 24 hour follow last study drug administration Day 9 . Adverse event , laboratory evaluation , electrocardiogram , physical examination , vital sign assess various time study .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>adult male subject , 21 45 year age , must medically healthy clinically significant screen result . history clinical evidence clinically relevant cardiovascular ( include thromboembolic disorder ) , hepatic , renal , hematological , endocrine , pulmonary , gastrointestinal , psychiatric neurological impairment ; clinically significant laboratory abnormality judge investigator ; systolic blood pressure &lt; 90 &gt; 120 mmHg ; diastolic blood pressure &lt; 50 &gt; 90 mmHg ; allergy previous adverse event PDE5 inhibitor , warfarin constituent ; use prescription overthecounter drug know interfere metabolism cytochrome P450 3A4 enzyme within 30 day screen ; use investigational drug within 30 day screen ; use prescription overthecounter drug herbal remedy within 14 day screen ; history alcohol drug abuse within 18 month , history smoking within 6 month ; positive urine alcohol drug test ; positive serum cotinine test ; positive serology HIV , HCV , HBsAg .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>ED</keyword>
</DOC>